A polyvanadate-based complex with anti-obesity and obesity-related inflammation-reducing effects, and preparation and application thereof
By preparing polyvanadate-based complexes, the problems of pet obesity and obesity-related inflammation have been solved, enabling simple and easy-to-implement pet weight control and health improvement, which is applicable to the preparation of pet food and drugs.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- SOUTH CHINA UNIV OF TECH
- Filing Date
- 2022-02-22
- Publication Date
- 2026-05-08
AI Technical Summary
Pet obesity leads to health problems, especially in cats and dogs, such as joint and skeletal disorders, breathing difficulties, internal organ diseases, and endocrine disorders. Existing pet food is expensive and has an unstable supply, and there is a lack of cost-effective solutions to control obesity and reduce obesity-related inflammation.
By mixing glucosamine hexavanadate with functional food additives, polyvanadate-based complexes are prepared for use in pet food or tablets to reduce pet weight and body fat percentage, reduce adipose tissue inflammation, and improve insulin resistance symptoms.
The simple and easy-to-implement preparation process effectively reduces pet weight and body fat percentage, alleviates inflammation of adipose tissue, improves pet health, and does not cause an increase in blood sugar levels, making it suitable for industrial production.
Smart Images
Figure HDA0003514040320000011 
Figure HDA0003514040320000012 
Figure HDA0003514040320000013
Abstract
Description
Technical Field
[0001] This invention belongs to the field of animal medicine, specifically relating to a polyvanadate complex with anti-obesity and anti-obesity-related inflammation properties, its preparation method, and its application. Background Technology
[0002] Pets play an important role in modern society, and many people find relief from negative emotions through spending time with them. However, cats and dogs, as pets, often suffer from obesity due to overfeeding caused by improper feeding practices. Obesity has a series of serious impacts on the health of cats and dogs, as well as on the lives of their owners. Obesity can cause joint and skeletal movement disorders in cats and dogs. Excess weight not only restricts their movement but can also put pressure on their joints, leading to problems such as intervertebral disc displacement, arthritis, and poor paw development. Obesity in cats and dogs can also cause breathing difficulties, which become more pronounced during exercise. Furthermore, obesity can cause internal organ diseases and endocrine disorders in cats and dogs, posing a serious threat to their health and life.
[0003] Obesity is closely related to nutritional and metabolic disorders, insulin resistance, and especially inflammation. For example, receptor-regulated serine / threonine protein kinase 1 (RIPK1), a key regulator of inflammatory cell function, is not only associated with inflammation, apoptosis, and necrosis under inflammatory stimulation, but also linked to the development of obesity in mammals at the genetic level. Furthermore, a recent study showed a high incidence of obesity in intensive care patients hospitalized for SARS-CoV-2. One characteristic of obesity is the accumulation of triglycerides and lipid droplets in viscera, which simultaneously increases the risk of developing type 2 diabetes. In obese animals, adipose tissue secretes large amounts of pro-inflammatory and anti-inflammatory cytokines, causing not only systemic chronic inflammation, but also exacerbating this chronic low-grade inflammation through macrophage infiltration. In excessively obese animals, white fat cells undergo excessive expansion, leading to local tissue hypoxia and necrosis, and consequently, various metabolic inflammations. Generally, pet owners control their pets' weight by feeding them low-calorie pet food that is high in protein, low in carbohydrates, high in fiber, and low in fat. However, these types of pet food are usually quite expensive, mostly imported products, and often out of stock through official channels. Therefore, developing cost-effective food and medication adjuvants to control the weight of cats and dogs is essential. Summary of the Invention
[0004] To address the shortcomings and deficiencies of existing technologies, the primary objective of this invention is to provide a polyvanadate complex that has anti-obesity and reduces obesity-related inflammation. This polyvanadate complex can significantly reduce the body weight and body fat mass of HFD mice (obese mice induced by a high-fat diet), reduce inflammation in their adipose tissue, and improve their insulin resistance symptoms, thereby improving the metabolic disorder status of the mice.
[0005] Another object of the present invention is to provide a method for preparing the aforementioned polyvanadate complex with anti-obesity and anti-obesity-related inflammation effects. The polyvanadate complex can be obtained by physically mixing a polyvanadate alkoxy derivative with a functional food additive.
[0006] Another object of the present invention is to provide the application of the above-mentioned polyvanadate complex with anti-obesity and anti-obesity-related inflammation properties in the preparation of pharmaceuticals and animal feeds.
[0007] The objective of this invention is achieved through the following technical solution:
[0008] A polyvanadate complex with anti-obesity and anti-obesity-related inflammation-reducing properties is composed of glucosamine hexavanadate and functional food additives in a mass ratio of 1:0.5 to 1:0.8.
[0009] The glucosamine hexavanadate is a tetradecanoic acid-modified glucosamine hexavanadate salt with a para-trihydroxy ligand substituted in the situ, wherein the trihydroxy ligand is trimethylolethyl tetradecanoate, and the molecular formula of the tetradecanoic acid-modified glucosamine hexavanadate is (C6H). 15 NO5)2[V6O 13 {(OCH2)3CCH2OOC(CH2) 12 [CH3}2], with a molecular weight of 1562.97.
[0010] The functional food additive is at least one of sorbitol, isomalt oligosaccharide, and galactooligosaccharide.
[0011] The preparation method of the above-mentioned polyvanadate complex with anti-obesity and anti-obesity-related inflammation includes the following steps:
[0012] (1) After cation exchange, tetrabutylammonium hexavanadate modified with tetradecanoic acid is mixed with glucosamine to obtain glucosamine hexavanadate (i.e., the polyvanadate alkoxy derivative).
[0013] (2) Mix the aqueous solution of glucosamine hexavanadate with the aqueous solution of functional food additives evenly and dehydrate at low temperature to obtain a polyvanadate complex with anti-obesity and anti-obesity-related inflammation.
[0014] Preferably, the tetradecanoic acid-modified tetrabutylammonium hexavanadate in step (1) can be prepared by referring to the method in the literature (A double-tailed fluorescent surfactant with a hexavanadate cluster as the headgroup. Angew. Chem., Int. Ed. 2011, 50, 2521-2525). More preferably, it can be prepared by the following specific method: tetrabutylammonium hexavanadate, tetradecanoic anhydride, 4-dimethylaminopyridine, triethylamine and acetonitrile are mixed evenly at a ratio of 1 mmol: 2 mmol: 2 mmol: 1 mmol: 20 mL. The solution is stirred at 80 °C for 48 h, cooled, and purified to obtain tetradecanoic acid-modified tetrabutylammonium hexavanadate.
[0015] Preferably, the tetrabutylammonium hexavanadate modified with tetradecanoic acid in step (1) is an ionic compound, the cation of which is tetrabutylammonium and the anion is [V6O 13 {(OCH2)3CCH2OOC(CH2) 12 CH3}2] 2- .
[0016] Preferably, the cation exchange in step (1) uses cations (H+) + The process involves ion exchange resin; specifically: cation (H+) exchange resin. + The cation exchange resin is packed into a glass tube with a piston at the bottom. The tetradecanoic acid-modified tetrabutylammonium hexavanadate solution flows slowly through the packed column and is eluted with pure water to complete the cation exchange.
[0017] Preferably, the glucosamine in step (1) is D-glucosamine with the chemical formula C6H4O2. 13 NO5.
[0018] Preferably, the molar ratio of tetrabutylammonium hexavanadate modified with tetradecanoic acid to glucosamine in step (1) is 1:2.
[0019] Preferably, the concentration of the glucosamine hexavanadate aqueous solution in step (2) is 10-15%.
[0020] Preferably, the mass concentration of the functional food additive aqueous solution in step (2) is 5-12%, more preferably 8%.
[0021] Preferably, the volume ratio of the glucosamine hexavanadate aqueous solution and the functional food additive aqueous solution in step (2) is 1:1.
[0022] Preferably, the dehydration temperature in step (2) is 30–50°C.
[0023] The above-mentioned polyvanadate complex with anti-obesity and anti-obesity-related inflammation effects is used in the preparation of drugs and animal feeds.
[0024] Its preferred application is in the preparation of animal medicine drugs, and even more preferred application is in the preparation of drugs for treating obesity and reducing obesity-related inflammation.
[0025] The technical principle of this invention: The polyvanadate complex of this invention is mainly prepared by mixing glucosamine hexavanadate with functional food additives. Glucosamine hexavanadate can reduce the body weight and body fat percentage of HFD-fed mice, reduce the accumulation of macrophages in the adipose tissue of HFD mice, increase the number and regulatory capacity of regulatory T cells (Treg cells) in adipose tissue, and reduce the number of inflammatory factors in adipose tissue, thereby alleviating systemic adipose tissue inflammation in HFD mice. The functional food additive can impart sweetness to the product and improve its taste without causing side effects such as increased blood glucose levels.
[0026] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0027] (1) The synthesis process of the polyvanadate complex with anti-obesity and anti-obesity-related inflammation described in this invention is relatively simple and easy to carry out, the product process quality is easy to control, which is conducive to industrial production, and the raw materials are readily available and the preparation method is simple.
[0028] (2) The polyvanadate complex with anti-obesity and anti-obesity-related inflammation of the present invention is mainly achieved by mixing glucosamine hexavanadate with functional food additives. The glucosamine hexavanadate can reduce the weight and body fat percentage of HFD-fed mice, thereby reducing the number of inflammatory factors in adipose tissue and alleviating systemic adipose tissue inflammation in HFD mice.
[0029] (3) The polyvanadate complex described in this invention, which has anti-obesity and reduces obesity-related inflammation, can be used as an additive in food or tablets for pets such as cats and dogs, so as to control the weight of pets such as cats and dogs and maintain their health. Attached Figure Description
[0030] Figure 1 ESI-MS mass spectrum (anion mode) of polyvanadate alkoxy derivatives.
[0031] Figure 2 This is the UV-Vis absorption spectrum of polyvanadate alkoxy derivatives.
[0032] Figure 3This is a comparison chart of mouse weight changes. The chart shows the weight changes of male C57BL / 5J mice fed a high-fat diet (HFD) and simultaneously administered the polyvanadate complex prepared in Example 1 orally for 8 weeks, compared to mice fed a normal rodent diet (NCD).
[0033] Figure 4 This is a comparison chart of changes in body fat in mice. Compared to mice fed a normal rodent diet (NCD), male C57BL / 5J mice fed a high-fat diet (HFD) and simultaneously orally administered the polyvanadate complex prepared in Example 1 for 8 weeks showed a comparison chart of changes in body fat in mice.
[0034] Figure 5 This is a comparison of changes in mouse macrophages. The comparison shows the changes in macrophages in male C57BL / 5J mice fed a high-fat diet (HFD) and simultaneously administered the polyvanadate complex prepared in Example 1 orally for 8 weeks, compared to mice fed a normal mouse diet (NCD).
[0035] Figure 6 This is a comparison of changes in mouse iNKT cells. The comparison shows the changes in mouse iNKT cells after C57BL / 5J male mice were fed a high-fat diet (HFD) and simultaneously orally administered the polyvanadate complex prepared in Example 1 for 8 weeks, compared to mice fed a normal mouse diet (NCD).
[0036] Figure 7 This is a comparison of changes in RIPK1 expression levels in mice. The graph shows the changes in RIPK1 expression levels in male C57BL / 5J mice fed a high-fat diet (HFD) and simultaneously orally administered the polyvanadate complex prepared in Example 1 for 8 weeks, compared to mice fed a normal rodent diet (NCD).
[0037] Figure 8 This is a comparison of changes in PPARγ expression levels in mice. The graph shows the changes in PPARγ expression levels in male C57BL / 5J mice fed a high-fat diet (HFD) and simultaneously administered the polyvanadate complex prepared in Example 1 orally for 8 weeks, compared to mice fed a normal mouse diet (NCD).
[0038] Figure 9 This is a comparative graph showing the changes in the production of the pro-inflammatory factor IFNα in mice. Compared with normal mouse diet (NCD), male C57BL / 5J mice fed a high-fat diet (HFD) and simultaneously orally administered the polyvanadate complex prepared in Example 1 for 8 weeks showed the changes in the production of the pro-inflammatory factor IFNα in mice.
[0039] Figure 10This is a comparative graph showing the changes in the production of the pro-inflammatory factor IL-6 in mice. Compared with normal mouse diet (NCD), male C57BL / 5J mice fed a high-fat diet (HFD) and simultaneously orally administered the polyvanadate complex prepared in Example 1 for 8 weeks showed the changes in the production of the pro-inflammatory factor IL-6 in mice.
[0040] Figure 11 This is a comparison chart showing the changes in the production of the anti-inflammatory factor IL-10 in mice. Compared with normal mouse diet (NCD), male C57BL / 5J mice fed a high-fat diet (HFD) and simultaneously orally administered the polyvanadate complex prepared in Example 1 for 8 weeks showed the changes in the production of the anti-inflammatory factor IL-10 in mice.
[0041] Figure 12 The image shows a comparison of mouse body weight. Compared to mice fed a normal diet (NCD), C57BL / 5J male mice were fed a high-fat diet (HFD) and simultaneously orally administered the polyvanadate complex prepared in Example 1, the glucosamine complex prepared in Comparative Example 1, the complex composed of hexavanadate and functional food additives prepared in Comparative Example 2, and the complex composed of tetradecanoic acid-modified hexavanadate and functional food additives prepared in Comparative Example 3. The mouse body weights are shown in the image.
[0042] Figure 13 This is a comparison chart of the production levels of the pro-inflammatory factor IFNα in mice. Compared with normal mouse diet (NCD), male C57BL / 5J mice fed a high-fat diet (HFD) and simultaneously orally administered the polyvanadate complex prepared in Example 1, the glucosamine complex prepared in Comparative Example 1, the complex composed of hexavanadate and functional food additives prepared in Comparative Example 2, and the complex composed of tetradecanoic acid-modified hexavanadate and functional food additives prepared in Comparative Example 3 for 8 weeks showed a comparison of the production levels of the pro-inflammatory factor IFNα in mice.
[0043] Figure 14 This is a comparison of RIPK1 expression levels in mice with inflammation. Compared to mice fed a normal diet (NCD), C57BL / 5J male mice were fed a high-fat diet (HFD) and simultaneously orally administered the polyvanadate complex prepared in Example 1, the glucosamine complex prepared in Comparative Example 1, the complex composed of hexavanadate and functional food additives prepared in Comparative Example 2, and the complex composed of tetradecanoic acid-modified hexavanadate and functional food additives prepared in Comparative Example 3. After 8 weeks, the expression levels of RIPK1 in these mice were compared. Detailed Implementation
[0044] The present invention will be further described in detail below with reference to the embodiments and accompanying drawings, but the implementation of the present invention is not limited thereto.
[0045] Unless otherwise specified in the embodiments of this invention, the conditions shall be performed according to conventional conditions or conditions recommended by the manufacturer. All raw materials and reagents used, unless otherwise specified, are commercially available conventional products.
[0046] Example 1
[0047] The tetradecanoic acid-modified tetrabutylammonium hexavanadate was prepared using the method described in the reference (A double-tailed fluorescent surfactant with a hexavanadate cluster as the headgroup. Angew. Chem., Int. Ed. 2011, 50, 2521–2525). Specifically, 1 mmol of tetrabutylammonium hexavanadate, 2 mmol of tetradecanoic anhydride, 2 mmol of triethylamine, 1 mmol of 4-dimethylaminopyridine, and 20 mL of acetonitrile were mixed thoroughly. The solution was placed in a round-bottom flask and stirred at 80 °C for 48 h. After the reaction was complete, the reaction solution was allowed to cool naturally to room temperature. The reaction solution was then filtered, the filtrate was collected, and the solvent was evaporated to collect the crystals, yielding the tetradecanoic acid-modified tetrabutylammonium hexavanadate. Subsequently, ion exchange was performed using a cation exchange resin (AMBERLITE XAD series resin, purchased from Aladdin). + The tetradecanoic acid-modified hexavanadate was then ion-exchanged and mixed thoroughly with 2 mmol of D-glucosamine to obtain glucosamine hexavanadate (i.e., the polyvanadate alkoxy derivative). Its mass spectrometry and UV-Vis absorption spectra are shown in the attached figure. Figure 1 and attached Figure 2 As shown in the mass spectrum, the mass peaks appearing in the mass spectrum correspond one-to-one with the molecular weights of the corresponding glucosamine hexavanadate anions with different negative charges. Then, a 12% (w / w) aqueous solution of glucosamine hexavanadate and an 8% (w / w) aqueous solution of sorbitol were mixed thoroughly at a volume ratio of 1:1. After removing half of the solvent at 40°C, a polyvanadate complex solution with anti-obesity and anti-obesity-related inflammation effects was obtained.
[0048] Example 2
[0049] The tetradecanoic acid-modified tetrabutylammonium hexavanadate was prepared using the method described in the reference (A double-tailed fluorescent surfactant with a hexavanadate cluster as the headgroup. Angew. Chem., Int. Ed. 2011, 50, 2521–2525). Specifically, 1 mmol of tetrabutylammonium hexavanadate, 2 mmol of tetradecanoic anhydride, 2 mmol of triethylamine, 1 mmol of 4-dimethylaminopyridine, and 20 mL of acetonitrile were mixed thoroughly. The solution was placed in a round-bottom flask and stirred at 80 °C for 48 h. After the reaction was complete, the reaction solution was allowed to cool naturally to room temperature. The reaction solution was then filtered, the filtrate was collected, and the solvent was evaporated to collect the crystals, yielding the tetradecanoic acid-modified tetrabutylammonium hexavanadate. Subsequently, ion exchange was performed using a cation exchange resin (AMBERLITE XAD series resin, purchased from Aladdin). + The tetradecanoic acid-modified hexavanadate was then ion-exchanged and mixed thoroughly with 2 mmol of D-glucosamine to obtain glucosamine hexavanadate (i.e., the polyvanadate alkoxy derivative). The mass spectrometry results are shown in the attached figure. Figure 1 As shown, the mass spectrum peaks that appear correspond one-to-one with the molecular weights of the corresponding glucosamine hexavanadate anions with different negative charges. Then, a 10% (w / w) aqueous solution of glucosamine hexavanadate and a 5% (w / w) aqueous solution of isomalt oligosaccharide were mixed evenly at a volume ratio of 1:1. After removing half of the solvent at 40°C, a polyvanadate complex solution with anti-obesity and anti-obesity-related inflammation effects was obtained.
[0050] Example 3
[0051] The tetradecanoic acid-modified tetrabutylammonium hexavanadate was prepared using the method described in the reference (A double-tailed fluorescent surfactant with a hexavanadate cluster as the headgroup. Angew. Chem., Int. Ed. 2011, 50, 2521–2525). Specifically, 1 mmol of tetrabutylammonium hexavanadate, 2 mmol of tetradecanoic anhydride, 2 mmol of triethylamine, 1 mmol of 4-dimethylaminopyridine, and 20 mL of acetonitrile were mixed thoroughly. The solution was placed in a round-bottom flask and stirred at 80 °C for 48 h. After the reaction was complete, the reaction solution was allowed to cool naturally to room temperature. The reaction solution was then filtered, the filtrate was collected, and the solvent was evaporated to collect the crystals, yielding the tetradecanoic acid-modified tetrabutylammonium hexavanadate. Subsequently, ion exchange was performed using a cation exchange resin (AMBERLITE XAD series resin, purchased from Aladdin). +The tetradecanoic acid-modified hexavanadate was then ion-exchanged and mixed thoroughly with 2 mmol of D-glucosamine to obtain glucosamine hexavanadate (i.e., the polyvanadate alkoxy derivative). The mass spectrometry results are shown in the attached figure. Figure 1 As shown, the mass spectrum peaks that appear correspond one-to-one with the molecular weights of the corresponding glucosamine hexavanadate anions with different negative charges. Then, a 15% (w / w) aqueous solution of glucosamine hexavanadate and a 12% (w / w) aqueous solution of galactooligosaccharides were mixed thoroughly at a volume ratio of 1:1. After removing half of the solvent at 40°C, a polyvanadate complex solution with anti-obesity and anti-obesity-related inflammation effects was obtained.
[0052] Example 4
[0053] The effects of the polyvanadate complex prepared in Example 1 on anti-obesity and reducing obesity-related inflammation are specifically illustrated.
[0054] Male C57BL / 6J mice, aged 6–7 weeks, were purchased from the Experimental Animal Research Center of South China University of Technology. After two weeks of acclimatization, they were fed a high-fat diet (HFD) containing 60% fat to establish an obesity model. Compared with mice fed a healthy diet, obese mice with a weight gain of more than 20% were selected for the following tests: obese mice (n=8 per group) were orally administered a polyvanadate complex solution (containing 100 μg of polyvanadate complex) and a high-fat diet (HFD) containing 60% fat once daily for 8 weeks. The control group was fed a normal chow diet (NCD) and physiological saline. Throughout the study, the weight, food consumption, and energy expenditure of each mouse were recorded. After the final week of the experiment, mice were euthanized, and adipose tissue was collected, weighed, and the levels of various immune factors were measured. Macrophage accumulation, the number of invariant natural killer T cells (iNKT), and the expression levels of receptor-interacting serine / threonine protein kinase 1 (RIPK1) mRNA and the activation levels of peroxisome proliferator-activated receptors α and γ (PPARα and PPARγ) were also determined. Frozen sections of adipose tissue were prepared. A portion of these frozen sections were stained with Oil Red stained to observe adipocyte proliferation and hypertrophy. Another portion of the frozen sections were stained with hematoxylin and eosin (H&E) to quantify macrophage regions. Finally, a final portion of the frozen sections was immunofluorescence labeled to observe iNKT cell proliferation.
[0055] After oral administration of 100 μg of the polyvanadate complex prepared in Example 1 once daily for 8 weeks, the average body weight of mice decreased from 35.68 g to 32.73 g, representing an average weight loss of 8.3% (see appendix). Figure 3Despite still being fed a high-fat diet, the obese mice had reached a weight close to that of normal mice. After daily administration of 100 μg of the polyvanadate complex prepared in Example 1 for 8 weeks, the average body fat mass of the mice decreased from 8.74 g to 4.22 g, representing an average reduction of 51.7% (see appendix). Figure 4 After daily administration of 100 μg of the polyvanadate complex prepared in Example 1 for 8 weeks, the accumulation of macrophages in mouse adipose tissue decreased by 51.7% (see appendix). Figure 5 After daily administration of 100 μg of the polyvanadate complex prepared in Example 1 for 8 weeks, the number of iNKT cells in T cells increased by 60.4% (see appendix). Figure 6 After daily administration of 100 μg of the polyvanadate complex prepared in Example 1 for 8 weeks, the expression level of RIPK1, which is associated with inflammation and cell necrosis, decreased (see appendix). Figure 7 The expression level of PPARγ, which is closely related to adipocyte differentiation, immunity, and insulin resistance, was increased (see appendix). Figure 8 After daily administration of 100 μg of the polyvanadate complex prepared in Example 1 for 8 weeks, the production of pro-inflammatory factors IFNα and IL-6 significantly decreased (see appendix). Figure 9 and attached Figure 10 The production of the anti-inflammatory factor IL-10 increased significantly (see appendix). Figure 11 Based on the above data, it can be concluded that after administering 100 μg of the polyvanadate complex prepared in Example 1 daily for 8 weeks, there was a certain degree of relief in the overall level of obesity-related inflammation.
[0056] Comparative Example 1
[0057] A complex of glucosamine and functional food additives was prepared. Specifically, a 12% (w / w) aqueous solution of D-glucosamine and an 8% (w / w) aqueous solution of sorbitol were mixed at a volume ratio of 1:1 until homogeneous. After removing half of the solvent at 40°C, a glucosamine complex solution was obtained.
[0058] Comparative Example 2
[0059] A complex of hexavanadate and a functional food additive was prepared. Specifically, 1.2 g of tetrabutylammonium hexavanadate was directly dispersed in 10 mL of an 8% (w / w) aqueous solution of sorbitol to obtain the complex of hexavanadate and the functional food additive.
[0060] Comparative Example 3
[0061] A complex of tetradecanoic acid-modified hexavanadate and a functional food additive was prepared. Specifically, tetradecanoic acid-modified tetrabutylammonium hexavanadate was prepared according to the method described in the reference (A double-tailed fluorescent surfactant with a hexavanadate cluster as the head group. Angew. Chem., Int. Ed. 2011, 50, 2521–2525). Specifically, 1 mmol of tetrabutylammonium hexavanadate, 2 mmol of tetradecanoic anhydride, 2 mmol of triethylamine, 1 mmol of 4-dimethylaminopyridine, and 20 mL of acetonitrile were mixed thoroughly. The solution was placed in a round-bottom flask and stirred at 80 °C for 48 h. After the reaction was completed, the reaction solution was allowed to cool naturally to room temperature, then filtered. The filtrate was collected, and the solvent was evaporated to collect the crystals, yielding tetradecanoic acid-modified tetrabutylammonium hexavanadate. Then, 1.2 g of tetradecanoic acid-modified tetrabutylammonium hexavanadate was dispersed in 10 mL of 8% (w / w) sorbitol aqueous solution to obtain the complex of tetradecanoic acid-modified hexavanadate and the functional food additive.
[0062] Comparative Example 4
[0063] The glucosamine complex prepared in Comparative Example 1, the complex composed of hexavanadic acid and functional food additives prepared in Comparative Example 2, and the complex composed of tetradecanoic acid-modified hexavanadic acid and functional food additives prepared in Comparative Example 3 are used to specifically illustrate the anti-obesity and anti-obesity-related inflammation effects of the polyvanadic acid complex prepared in Example 1.
[0064] Male C57BL / 6J mice, aged 6–7 weeks, were purchased from the Experimental Animal Research Center of South China University of Technology. After two weeks of acclimatization, they were fed a high-fat diet (HFD) containing 60% fat to establish an obesity model. Compared with mice fed a healthy diet, obese mice with a weight gain of at least 20% were selected for the following tests: A total of 32 obese mice were divided into four groups of 8 mice each. The first group of obese mice was orally administered once daily with a polyvanadate complex solution (containing 100 μg, or 0.038 μmol / L of tetradecanoic acid-modified glucosamine hexavanadate prepared in Example 1) for 8 weeks. The second group of obese mice was orally administered once daily with a glucosamine complex solution (containing 23 μg, or 0.076 μmol / L of D-glucosamine from Comparative Example 1) for 8 weeks. The third group of obese mice was orally administered once daily with a complex solution of hexavanadate and functional food additives (containing 76 μg, or 0.038 μmol / L of tetrabutylammonium hexavanadate prepared in Comparative Example 2) for 8 weeks. The fourth group of obese mice was orally administered once daily with a complex solution of tetradecanoic acid hexavanadate and functional food additives (containing 108 μg, or 0.038 μmol / L of tetradecanoic acid-modified tetrabutylammonium hexavanadate prepared in Comparative Example 3) for 8 weeks. All four groups of obese mice were simultaneously fed a high-fat diet containing 60% fat daily. The control group was fed a normal chow diet (HFD). Throughout the study, the weight, food consumption, and energy expenditure of each mouse were recorded.
[0065] Eight weeks later, the mice in the first group, which were given the polyvanadate complex solution, showed a significant decrease in body weight (see attached). Figure 12 The weight of mice in the first group (normal mice) increased, and they were close to the control group. The second group of mice, given a glucosamine complex solution, continued to gain weight, becoming the highest-weighted group. The third group of mice, given a complex solution of hexavanadic acid and functional food additives, experienced a slight decrease in weight, but the reduction was significantly less than that of the first group. The fourth group of mice, given a complex solution of tetradecanoic acid, hexavanadic acid, and functional food additives, also experienced a slight decrease in weight, similar to the third group. This demonstrates that glucosamine complex solution is ineffective in reducing mouse weight and lacks the ability to reduce mouse weight. Both hexavanadic acid and tetradecanoic acid-modified hexavanadic acid can reduce mouse weight to some extent, but the weight loss effect is significantly less than that of polyvanadic acid complexes (see attached diagram). Figure 12 ).
[0066] Eight weeks later, the levels of inflammatory factors in the first group of mice given the polyvanadate complex solution were significantly reduced (taking IFNα and RIPK1 as examples, see attached). Figure 13 and attached Figure 14The levels of inflammatory factors in the first group of mice were relatively close to those in the control group (normal mice). The second group of mice treated with the glucosamine complex solution still showed high levels of IFNα, and the glucosamine complex had no significant effect on RIPK1 expression. Although glucosamine itself has some anti-inflammatory effects, at the current dosage, it was difficult to significantly affect obesity-related inflammation in mice. The third group of mice treated with a complex solution composed of hexavanadic acid and functional food additives maintained high levels of inflammatory factors, indicating that the complex solution had no significant effect on alleviating obesity-related inflammation in mice. The fourth group of mice treated with a complex solution composed of tetradecanoic acid hexavanadic acid and functional food additives also showed a certain decrease in inflammatory factor levels, but did not show a good effect on regulating obesity-related inflammation in mice. Therefore, the hexavanadic acid complex solution cannot effectively reduce the levels of inflammatory factors in mice and does not have the ability to effectively alleviate inflammation in mice. While tetradecanoic acid-modified hexavanadic acid has some ability to alleviate inflammation in mice, its effect on reducing obesity-related inflammation in mice is significantly less than that of the polyvanadic acid complex (see attached diagram). Figure 13 and attached Figure 14 ).
[0067] The above embodiments are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above embodiments. Any changes, modifications, substitutions, combinations, or simplifications made without departing from the spirit and principle of the present invention shall be considered equivalent substitutions and shall be included within the protection scope of the present invention.
Claims
1. A polyvanadate complex with anti-obesity and anti-obesity-related inflammation-reducing properties, characterized in that, It is a compound made of glucosamine hexavanadate and functional food additives in a mass ratio of 1:0.5 to 1:0.8; The glucosamine hexavanadate is a tetradecanoic acid-modified glucosamine hexavanadate salt, and the molecular formula of the tetradecanoic acid-modified glucosamine hexavanadate is (C6H). 15 NO5)2[V6O 13 {(OCH2)3CCH2OOC(CH2) 12 CH3}2]; The functional food additive is at least one of sorbitol, isomalt oligosaccharide, and galactooligosaccharide.
2. The method for preparing the polyvanadate complex with anti-obesity and anti-obesity-related inflammation effects as described in claim 1, characterized in that, Includes the following steps: (1) After cation exchange, tetrabutylammonium hexavanadate modified with tetradecanoic acid is mixed with glucosamine to obtain glucosamine hexavanadate. (2) Mix the aqueous solution of glucosamine hexavanadate with the aqueous solution of functional food additives evenly and dehydrate at low temperature to obtain a polyvanadate complex with anti-obesity and anti-obesity-related inflammation.
3. The method for preparing a polyvanadate-based complex with anti-obesity and anti-obesity-related inflammation effects according to claim 2, characterized in that, The tetradecanoic acid-modified tetrabutylammonium hexavanadate salt described in step (1) is an ionic compound, with tetrabutylammonium as its cation and [V6O] as its anion. 13 {(OCH2)3CCH2OOC(CH2) 12 CH3}2] 2- The glucosamine mentioned in step (1) is D-glucosamine.
4. The method for preparing a polyvanadate-based complex with anti-obesity and anti-obesity-related inflammation effects according to claim 2, characterized in that, In step (1), the molar ratio of tetrabutylammonium hexavanadate modified with tetradecanoic acid to glucosamine is 1:
2.
5. The method for preparing a polyvanadate-based complex with anti-obesity and anti-obesity-related inflammation effects according to claim 2, characterized in that, The cation exchange in step (1) is performed using a cation exchange resin.
6. The method for preparing a polyvanadate-based complex with anti-obesity and anti-obesity-related inflammation effects according to claim 2, characterized in that, In step (2), the mass concentration of the glucosamine hexavanadate aqueous solution is 10-15%; the mass concentration of the functional food additive aqueous solution is 5-12%; and the volume ratio of the glucosamine hexavanadate aqueous solution to the functional food additive aqueous solution is 1:
1.
7. The method for preparing a polyvanadate-based complex with anti-obesity and anti-obesity-related inflammation effects according to claim 2, characterized in that, The dehydration temperature in step (2) is 30–50 °C.
8. The application of the polyvanadate complex of claim 1, which has anti-obesity and anti-obesity-related inflammation effects, in the preparation of anti-obesity drugs and animal feeds.
9. The application of the polyvanadate complex with anti-obesity and anti-obesity-related inflammation properties as described in claim 1 in the preparation of anti-obesity animal medicines.